Aíma

Aíma develops advanced liquid biopsy tests for minimal residual disease and early cancer detection.
Our whole-genome methylation and fragmentomics platform combines AI with ultra-sensitive sequencing to detect cancer DNA and determine its tissue of origin.

We collaborate with leading clinical centers to bring faster, more accurate and more accessible cancer diagnostics to patients.